On Wednesday, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted for expanded usage recommendation for Merck & Co Inc's (NYSE:MRK) and Pfizer Inc's (NYSE:PFE) pneumococcal conjugate vaccines.
The CDC panel has recommended lowering the pneumococcal vaccination age from 65 to 50 years old.
"ACIP's vote to expand adult pneumococcal vaccination to now include all adults aged 50 and older marks an important milestone in Pfizer's long-standing commitment to reducing the burden of this life-threatening disease," Pfizer's chief medical affairs officer for global vaccines and antivirals, said Luis Jodar.
The 20 serotypes contained in Pfizer's PREVNAR 20 are estimated to cause over 2,000 deaths and more than 65,000 cases of invasive pneumococcal disease (IPD), including bacteremia and meningitis and community-acquired pneumonia annually in adults aged 50 to 64.
Between 2018 and 2022, more than half of IPD cases in people aged 50 to 64 were caused by these 20 serotypes.
In the presentation, ACIP highlighted that among adults aged 50–64 with pneumococcal disease, a high proportion (88%) of adults
had ≥1 condition with a risk-based pneumococcal vaccine indication.
The CDC's pneumococcal vaccines workgroup emphasized in its presentation that an age-based recommendation would likely increase vaccine uptake more effectively than a risk-based approach.
The expert panel also highlighted economic impact, serotype coverage, and health equity advantages to support its recommendation.
In June this year, the FDA approved Merck's Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.
It's the first pneumococcal conjugate vaccine specifically designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection.
Price Action: At the last check on Thursday, MRK stock was down 0.73% at $105.60, and PFE stock was down 1.02% at $28.57.
週三，美國疾病控制與預防中心（CDC）免疫實踐諮詢委員會（ACIP）投票通過了擴大默沙東公司（紐約證券交易所代碼：MRK）和輝瑞公司（紐約證券交易所代碼：PFE）肺炎球菌偶聯疫苗的使用建議。
疾病預防控制中心小組建議將肺炎球菌疫苗接種年齡從65歲降低到50歲。
輝瑞全球疫苗和抗病毒藥物首席醫學事務官路易斯·喬達爾說：「ACIP投票決定將成人肺炎球菌疫苗接種範圍擴大到現在包括所有50歲及以上的成年人，這標誌着輝瑞長期致力於減輕這種危及生命的疾病負擔的一個重要里程碑。」
據估計，輝瑞PREVNAR 20中包含的20種血清型每年在50至64歲的成年人中造成2,000多例死亡和超過65,000例侵入性肺炎球菌病（IPD）病例，包括菌血症和腦膜炎以及社區獲得性肺炎。
在2018年至2022年之間，50至64歲人群中超過一半的IPD病例是由這20種血清型引起的。
在演講中，ACIP強調，在50-64歲患有肺炎球菌病的成年人中，成年人的比例很高（88％）
根據肺炎球菌疫苗的風險指示，患有 ≥1 種病症。
疾病預防控制中心的肺炎球菌疫苗工作組在其發言中強調，與基於風險的方法相比，基於年齡的建議可能會更有效地提高疫苗的吸收率。
專家小組還強調了經濟影響、血清型覆蓋範圍和健康公平優勢，以支持其建議。
今年6月，美國食品藥品管理局批准了默克公司的Capvaxive（肺炎球菌21價偶聯疫苗），用於預防21種細菌菌株，預防嚴重的肺炎球菌疾病。
這是第一種專門爲保護成年人免受肺炎球菌的細菌侵害而設計的肺炎球菌偶聯疫苗，這種細菌可能導致嚴重疾病和肺部感染。
價格走勢：在週四的最後一次檢查中，MrK股價下跌0.73％，至105.60美元，PFE股價下跌1.02％，至28.57美元。
